bruno vincenzi
bruno vincenzi
Affiliazione sconosciuta
Email verificata su unicampus.it
Titolo
Citata da
Citata da
Anno
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective …
W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ...
The lancet oncology 11 (8), 753-762, 2010
20382010
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ...
British journal of cancer 101 (4), 715-721, 2009
5872009
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients
D Santini, B Vincenzi, G Dicuonzo, G Avvisati, C Massacesi, F Battistoni, ...
Clinical Cancer Research 9 (8), 2893-2897, 2003
3762003
Pamidronate induces modifications of circulating angiogenetic factors in cancer patients
D Santini, B Vincenzi, G Avvisati, G Dicuonzo, F Battistoni, M Gavasci, ...
Clinical Cancer Research 8 (5), 1080-1084, 2002
3222002
Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients
C Raimondi, A Gradilone, G Naso, B Vincenzi, A Petracca, C Nicolazzo, ...
Breast cancer research and treatment 130 (2), 449-455, 2011
2822011
Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB–IIA non-small cell lung cancer
TC Mineo, V Ambrogi, A Baldi, C Rabitti, P Bollero, B Vincenzi, G Tonini
Journal of clinical pathology 57 (6), 591-597, 2004
2702004
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice
D Santini, F Loupakis, B Vincenzi, I Floriani, I Stasi, E Canestrari, E Rulli, ...
Oncologist 13 (12), 1270, 2008
2692008
The antineoplastic role of bisphosphonates: from basic research to clinical evidence
D Santini, U Vespasiani Gentilucci, B Vincenzi, A Picardi, F Vasaturo, ...
Annals of Oncology 14 (10), 1468-1476, 2003
2012003
Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in …
D Santini, B Vincenzi, S Galluzzo, F Battistoni, L Rocci, O Venditti, ...
Clinical Cancer Research 13 (15), 4482-4486, 2007
1922007
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib
B Vincenzi, D Santini, A Russo, R Addeo, F Giuliani, L Montella, S Rizzo, ...
The oncologist 15 (1), 85, 2010
1842010
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy
A Ruzzo, F Graziano, K Kawakami, G Watanabe, D Santini, V Catalano, ...
J Clin Oncol 24 (12), 1883-1891, 2006
1772006
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients
D Santini, G Schiavon, B Vincenzi, L Gaeta, F Pantano, A Russo, ...
PloS one 6 (4), e19234, 2011
1712011
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients
B Vincenzi, D Santini, G Dicuonzo, F Battistoni, M Gavasci, A La Cesa, ...
Journal of interferon & cytokine research 25 (3), 144-151, 2005
1712005
Emerging anti-cancer molecular mechanisms of aminobisphosphonates
M Caraglia, D Santini, M Marra, B Vincenzi, G Tonini, A Budillon
Endocrine-related cancer 13 (1), 7-26, 2006
1522006
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
D Santini, B Vincenzi, R Addeo, C Garufi, G Masi, M Scartozzi, A Mancuso, ...
Annals of Oncology 23 (9), 2313-2318, 2012
1512012
Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization
A Gradilone, G Naso, C Raimondi, E Cortesi, O Gandini, B Vincenzi, ...
Annals of Oncology 22 (1), 86-92, 2011
1462011
Fever after zoledronic acid administration is due to increase in TNF-α and IL-6
G Dicuonzo, B Vincenzi, D Santini, G Avvisati, L Rocci, F Battistoni, ...
Journal of interferon & cytokine research 23 (11), 649-654, 2003
1442003
Cetuximab: from bench to bedside
B Vincenzi, A Zoccoli, F Pantano, O Venditti, S Galluzzo
Current cancer drug targets 10 (1), 80, 2010
1372010
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases
D Santini, G Perrone, I Roato, L Godio, F Pantano, D Grasso, A Russo, ...
Journal of cellular physiology 226 (3), 780-784, 2011
1342011
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study
P Sperone, A Ferrero, F Daffara, A Priola, B Zaggia, M Volante, D Santini, ...
Endocrine-related cancer 17 (2), 445-453, 2010
1322010
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20